Welcome to our dedicated page for Health Catalyst SEC filings (Ticker: HCAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Locating the story behind Health Catalyst’s adaptive data platform inside a 300-page filing can feel overwhelming. Revenue split between Technology subscriptions and Professional Services, HIPAA risk factors, and contract backlog all sit deep in footnotes—yet they drive valuation. If you have ever asked, “Where can I find the Health Catalyst quarterly earnings report 10-Q filing?” or searched for “Health Catalyst insider trading Form 4 transactions,” this page removes the friction.
Stock Titan’s AI reads every submission the instant it hits EDGAR and surfaces exactly what matters. Our tool converts a dense Health Catalyst annual report 10-K simplified into plain language, flags new 8-K material events explained, and delivers Health Catalyst Form 4 insider transactions real-time so you spot executive stock moves without parsing tables. Need context on incentive plans? The Health Catalyst proxy statement executive compensation section is summarized alongside key metrics. You will also find links to each Health Catalyst earnings report filing analysis, plus guidance for understanding Health Catalyst SEC documents with AI if you are new to regulatory language.
Whether you are monitoring segment margin trends, tracking Health Catalyst executive stock transactions Form 4, or comparing sequential growth across hospitals served, every disclosure type—from 10-Q updates to 8-K contract wins—is here with real-time alerts. Analysts use these insights to model recurring revenue, portfolio managers watch insider buys for conviction signals, and healthcare strategists examine risk factor evolution. Explore the complete library now and see Health Catalyst SEC filings explained simply—so your next decision starts with clarity, not complexity.
Health Catalyst, Inc. reported revenue of $160.1 million for the six months ended June 30, 2025, up from $150.6 million a year earlier, driven by higher recurring technology revenue of $104.4 million (vs. $94.6 million). Despite revenue growth, operating costs and a $28.8 million goodwill impairment contributed to a wider six-month net loss of $64.7 million, or $0.94 per share, compared with a $34.1 million loss a year ago.
Cash and cash equivalents declined sharply to $50.7 million from $249.6 million at year-end, reflecting cash used to settle long-term obligations including the full cash settlement of convertible senior notes and acquisition activity (notably the Upfront acquisition with $80.0 million consideration). Total assets fell to $616.2 million and total liabilities to $268.6 million, leaving stockholders' equity of $347.5 million.
Form 3 overview – Health Catalyst, Inc. (HCAT): On 06/25/2025, Chief Technology & Product Officer David Coy Ross filed an initial statement of beneficial ownership. The filing discloses direct ownership of 207,579 common shares, consisting of previously issued stock plus multiple tranches of restricted stock units (RSUs) granted under the 2019 Stock Option and Incentive Plan. The RSUs follow customary quarterly-vesting schedules, with the largest award (90,000 RSUs) beginning to vest on 12/01/2025 (33.33%) and the balance in eight equal quarterly installments. No derivative securities, purchases, or sales were reported; the Form 3 simply records the officer’s existing equity position as required under Section 16(a). The disclosure signals equity alignment between the newly reported executive and shareholders but does not by itself imply any immediate financial impact on HCAT.
FAQ
What is the current stock price of Health Catalyst (HCAT)?
What is the market cap of Health Catalyst (HCAT)?
